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Microglia are Involved in Pain Related Behaviors during the Acute 
and Chronic Phases of Arthritis Inflammation 
 
 
Behzad Nasseri1,2, Vida Nazemian1,2, Homa Manaheji1,2, Jalal Zaringhalam1,2* 
 
Abstract 
Background: Pain is one of the main protests of inflammatory diseases, 
hence, understanding the mechanisms which involved in the induction and 
persistence of pain is essential. Microglia is a contributing factor in the onset 
and maintenance of inflammation. Increased microglial activation increases 
the level of central pro-inflammatory cytokines and the development of 
central sensitization following inflammation. The aim of this study was 
evaluated the relation of spinal microglia activity with pain related behaviors 
during Complete Freund’s adjuvant (CFA)-induced inflammation.  
Materials and Methods: Inflammation caused by subcutaneous injection of 
Complete Freund’s adjuvant (CFA) in a single dose to the animal’s right hind 
paw. The edema and hyperalgesia caused by inflammation, respectively, were 
measured by Plethysmometer and Radiant Heat, on days 0, 7, 14, and 21. 
Spinal Iba-1 protein expression was detected by Western blotting. 
Minocycline hydrochloride (Sigma, U.S.A) was administered intraperitoneal 
at a dose of 40 mg/kg daily.  
Results: Our study findings indicated that CFA injection to the right hind 
paw of rats increased paw volume and hyperalgesia significantly during 
different stages of study, while Minocycline treatment significantly reduced 
paw volume and hyperalgesia. CFA injection into the right hind paw of the 
rat increases the expression of molecules ionized calcium binding adaptor 
molecule-1 (Iba-1) on different days of study, while Minocycline 
administration reduced spinal Iba-1 expression significantly compared to 
the CFA group.  
Conclusion: The results of this study indicated significant roles of microglia 
activation in deterioration of pain related behaviors during different stages of 
CFA-induced inflammation. The steady injection of Minocycline (as a 
microglia inhibitor) could reduce the inflammatory symptoms.  
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Introduction 
Rheumatoid arthritis (RA) is a chronic 
autoimmune disorder causing inflammation of the 
joints and surrounding tissues (1). Inflammation is 
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part of the non-specific immune response that occurs 
in reaction to any type of bodily injury. In some 
disorders, the inflammatory process -which under 
normal conditions is self-limiting- becomes 
continuous and chronic inflammatory diseases might 
develop subsequently (2).  
Inflammatory responses in the peripheral and 
central nervous systems play key roles in the 
development and persistence of many pathological 
pain states (3). Much research in recent years focused 
on the role of microglia in maintenance of pain (4). 
Microglial cells represent the immune system at the 
spinal cord level and comprise as little as 5–20% of 
all glial cells in physiological functions (5, 6). Studies 
indicated followed the peripheral nerve injury, 
microglial cells are strongly activated in the animal 
neuropathic pain model both in the DRGs and at the 
spinal level (7). Microglia cells are sensitive to 
changes in their environment and quickly activated in 
response to pathogens and inflammation (8). 
Peripheral inflammation often results in inflammatory 
pain associated with hyperalgesia and allodynia (9).  
Various inflammatory mediators in response to 
inflammation will be released from blood cells and 
damaged tissue including histamine, bradykinin and 
pro-inflammatory cytokines (10). Primary afferent 
nociceptor sensitization with cytokines is the 
consequence of damage to tissues (11). Increasing of 
excitatory signal transition from primary afferent 
fibers to dorsal horn neuron can cause central 
sensitization and pursuantly induction of hyperalgesia 
and allodynia (12). It was known that microglial cells 
are one of the important factors in the induction and 
maintenance of inflammation (13).   
Acute inflammation in rats, after increases of 
inflammatory cytokines which induced by adjuvant 
can activates microglia in the lumbar spinal cord (14). 
Studies have shown microglia activation in response 
to inflammation and subsequent increase of pro-
inflammatory cytokines, plays a key role in the 
development of central sensitization following 
peripheral nerve injury or inflammation (15, 16). 
Central pro-inflammatory cytokines primarily 
produced by microglia and have key role in central 
sensitization and chronic pain (17, 18). Central 
cytokines through presynaptic and postsynaptic 
mechanism increases the activity of excitatory 
synapses in the spinal cord, resulting in the 
development of central sensitization (12, 19).  
Inflammation caused by plantar injection of 
complete Freund’s adjuvant (CFA), commonly used 
as an animal model for acute and chronic 
inflammatory pain (20). Our previous studies have 
shown that CFA induced inflammation reduces 
peripheral afferents stimulation threshold in the spinal 
cord, which ultimately leads to hyperalgesia and 
edema during first week after the intervention. CFA 
induced inflammation, is a two-phase model. The first 
phase (phase of inflammation) is associated with 
increased pain due to the presence of pro-
inflammatory cytokines, while in the second phase 
(Phase of arthritis) dramatically reduced hyperalgesia 
(21). Minocycline, a tetracycline-like anti-biotic, has 
been used as a microglial activation inhibitor and 
shown to ameliorate several neurodegenerative 
conditions (22). Then, based on the potency of 
minocycline in inhibition the microglia activity, in 
this study, the effects of minocycline on behavioral 
aspects of inflammatory arthritic pain induced by 
CFA was investigated. 
Methods 
Animals 
Adult male Wistar rats with an average weight 
of 200-220 gr were used for this study. Rats were 
housed at a temperature of 22±2°C with a 12h light–
dark cycle, and fed food and water ad libitum. The 
animals were allowed to habituate to the housing 
facilities for at least 1 week before the experiments 
were begun.  All procedures were approved by the 
local ethics committee for the use of animals in 
research, and the guidelines of the International 
Association for the Study of Pain (23).  
Local paw inflammation induction 
Complete Freund’s adjuvant (CFA), heat-killed 
mycobacterium tuberculosis (Sigma, St. Louis, MO, 
USA) suspended in a sterile mineral oil (10 mg/ml), 
was injected on Day 0 subcutaneously into the plantar 
surface of the right hind paw. Right hind paw of the 
control rats was only injected with sterile mineral oil 
(100μl). First day after CFA injection unilateral 
inflammation was established in injected hind paw, 
then first week was considered as inflammatory 
phase. The third week after intervention was arthritic 
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phase. 
Assessment of CFA-induced inflammation and 
paw edema 
Arthritis due to CFA injection was assessed by 
measurements of paw volumes pre- and post-injection 
(on days 0, 7, 14 and 21). Measurements (paw 
volume) were conducted by displacement of an 
electrolyte solution in a plethysmometer (model 7141; 
Ugo Basile; Comerio VA, Italy). The rats’ hind paw 
were submerged up to the tibiotarsal joint in the 
electrolyte-filled Perspex cell of the plethysmometer. 
The volume of liquid displacement, which is 
correlated to the paw volume, was indicated on a 
digital displayer. Volume measurements were 
conducted twice for each paw, and the average 
volume displacement was calculated. The volumes 
measured on days post-injection were calculated as 
the percentage of the day 0 volume (24).  
Thermal hyperalgesia assessment 
Paw withdrawal latency (PWL) from noxious 
heat by using the plantar test (Ugo Basile, Verse, 
Italy) was assessed in different experimental and 
control rats on days 0 (before injection of CFA), 7, 
14, and 21. Rats were placed in Plexiglas boxes for 
10–15 min before testing in order to habituate to test 
environment. The heat source was positioned under 
the plantar surface of the affected hind paw and 
activated. PWL automatically recorded by digital 
timer which connected to the heat source. If the rat 
did not withdraw its paw from stimulus by 20s, the 
test was terminated and the rat was assigned this cut-
off value. Withdrawal latency was measured three 
times for each hind paw at an interval of 5– 10 min 
and the mean latency was calculated. Then, the mean 
value for the affected paw (CFA-injected paw) was 
subtracted from that for the other paw and the result 
considered as the hyperalgesia sign in the injured 
paw.  
Drug preparation 
Minocycline hydrochloride (Sigma, U.S.A) 
was dissolved in 0.9% saline. It was administered 
intraperitoneal at a dose of 40 mg/kg daily (24). 
Western blot analysis 
After behavioral tests, western blot was used to 
measure the levels of Iba-1 (as a specific marker of 
microglial activation) of the sample isolated from 
lumbar spinal cord of rats. Briefly, the rats were killed 
rapidly in a CO2 chamber. Then the lumbar spinal 
cord was quickly removed on ice, and homogenized 
(Brinkman polytron homogenizer, 20000 rpm for 30 
s) in the lysis buffer containing proteinase inhibitors 
(Sigma). The extracted proteins were harvested for 
analysis and concentration of proteins are identified. 
Samples were separated by electrophoresis and the 
proteins transferred to poly vinylidene difluoride 
filters (PVDF) (Millipore). The status of non-specific 
bands on PVDF paper with incubation (90 minutes at 
24°C) in blocking buffer blocked. Incubation was 
done with primary antibody in blocking buffer (Goat 
polyclonal to Iba1), (1:2000); Abcam/ ab5076) for 1 h 
at 24°C continues. Then membranes washed three 
times with TBST buffer (Tris-buffered saline with 
Tween 20) and then incubated with secondary 
antibody in blocking buffer (Anti-Goat (1:10,000); 
Abcam/CA) for 1 h at 24°C. The papers washed three 
times with TBST. The membranes were then 
incubated in stripping buffer and reported with beta-
actin primary antibody (1:5000; Cell Signaling) as a 
loading control. The protein immune response can be 
seen on paper with identification system 
chemoimmunoluminens. To ensure the detection of 
microglia, the Iba-1 is measured relative to beta-actin. 
Bond concentration of densitometry using NIH Image 
with measured and reported. Each test is repeated 3 
times for each group (25). 
Experimental procedures 
In order to determine the effect of minocycline 
on inflammatory pain model and the effectiveness of 
the treatment, a series of experiments were 
performed. Rats were randomly divided into different 
experimental groups, as follows: (a) CFA group, (b) 
CFA control group, (c) CFA + Minocycline (d) 
CFA+0.9% saline.  
According to the study procedure, each group 
was divided into four subgroups based on different 
time points of the study (days 0, 7, 14, and 21) and 
there were 6 rats in each subgroup. Inflammation 
induction is done on day zero. The CFA control group 
was received sterile mineral oil once only (100μL) 
(S.C.). From the first day after CFA injection, 
experimental groups received the minocycline 
intraperitoneal (i.p.) 40 mg/kg daily. Normal saline as 
diluents of minocycline was used in control groups 
(showed as a 0.9% saline + CFA group) and the 
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assessments were fully performed as the minocycline 
+ CFA groups. At the end of each period (days 0,7, 
14, 21), after conducting behavioral tests, the rats 
were killed rapidly, then, lumbar spinal cord of rats 
was isolated on ice for western blot, used to measure 




Results are presented as the Mean ± SEM. Data 
was analyzed by one way analysis of variance 
(ANOVA), followed by Post hoc Tukey’s test for 
multiple comparison. Unpaired Student’s t-test was 
used to determine significant differences between the 
groups. An effect was determined to be significant if 
the p-value was less than 0.05. The p value of less 
than 0.05 was considered as statistically significant. 
Results 
Variation of Paw volume during different stages of 
study 
CFA injection into the right hind paw caused a 
significant increase in paw volume (edema) which 
was continued until the 21st day of the study. Right 
injected paw volume showed a significant increase on 
days 7, 14, and 21 after CFA injection compared to 
day 0 and with CFA control group (p≤0.01 for day 7 
and p≤0.001 for day 14 and 21). There were no 
significant differences in reduction in paw volume 
following injection of sterile mineral oil to the rat’s 
right hind paw on different days of the study relative 
to baseline in the CFA control group (Fig. 1). 
Daily administration (i.p.) of Minocycline in 
the CFA+ Minocycline group significantly reduced 
paw volume. Minocycline injection in the group 
significantly reduced paw volume compared to the 
same days in CFA group throughout this study 
(p≤0.001 for days 14 and 21). In comparison between 
the groups CFA+ Minocycline and CFA, the results 
illustrated that reduction of paw edema following the 
injection of Minocycline, at day 21 was higher than 
day 14 substantially (p≤0.01). However Minocycline 
treatment decremented paw volume in the CFA+ 
Minocycline group, so that at day 21 of the 
experiment, no significant distinction in paw volume 
in CFA+ Minocycline group compared with CFA 
control group was perceived (Fig. 2). In addition, 
 
Fig. 1. CFA injection caused significant edema in 
affected paw which continued till 21 days of study. 
Long-term Minocycline treatment significantly 
reduced inflamed paw volume. Results presented as 
Mean ± SEM (n=6/group).  
** p≤0.01 and *** p≤0.001 for comparing the paw 
volume variations between baseline and different 
days of the study in CFA group. # p≤0.05 and # # 
p≤0.01 for comparing the paw volume variations 
between day 0 and different days of the study in 
CFA+ Minocycline group. Δ p≤0.05 and ΔΔ 
p≤0.01 for illustrating the variations in paw volume 
at day 14 and day 21 compared to day7 in the 
CFA+ Minocycline group. 
 
Fig. 2. CFA injection increased paw volume 
significantly, while Minocycline administration 
caused a remarkable reduction in paw volume 
compared with CFA group. Results stated as 
Mean± SEM (n=6/group). ** p≤0.01 and *** 
p≤0.001 for comparing the paw volume variations 
between CFA and CFA+ Minocycline groups in 
identical days. # p≤0.05 and # # p≤0.01 for 
comparing the paw volume variations between 
CFA+ Minocycline and CFA control groups in 
identical days. †† p≤0.01 for comparing the 
differences in paw volume alterations in CFA and 
CFA+ Minocycline groups at day 14 compared to 
day 21. 
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there were no significant differences in paw volume 
of rats during 21 days of the study in CFA+0.9% 
saline (as a vehicle of Minocycline) group (Hence, the 
results of the CFA+0.9% saline groups are not shown 
graphically). 
Thermal hyperalgesia Variations during different 
stages of study 
Thermal hyperalgesia varied in the right 
(injected) paw during different stages of 
inflammation. Hyperalgesia significantly increased on 
day 7 after CFA injection compared to day 0 in the 
CFA group (p<0.001), but our results also indicated 
that inflammation continuation caused hyperalgesia to 
decrease on days 14 and 21. However, there was still 
a significant increase compared to day 0 (p≤0.01). 
There were no significant differences in reduction of 
thermal hyperalgesia following injection of sterile 
mineral oil to the rat’ right hind paw on different days 
of the study relative to baseline in the CFA control 
group. Daily administration (i.p.) of Minocycline in 
the CFA+ Minocycline group reduced hyperalgesia 
(Fig. 3).  
Minocycline injection in the CFA+ 
Minocycline group significantly reduced thermal 
hyperalgesia compared to the same days in CFA 
group throughout this study (p≤0.01 for day 7 and 
p≤0.001 for days 14 and 21). In comparison between 
the CFA and CFA+ Minocycline groups, the results 
illustrated that the rate of reduction of thermal 
hyperalgesia following the injection of Minocycline, 
at days 21th and 14th after CFA injection between 
these two groups was higher than day 7 (p≤0.001). 
Continuing injection of Minocycline decremented 
PWL in CFA+ Minocycline group, so that at day 21 
of the study, no significant difference in PWL in 
CFA+ Minocycline group compared with CFA 
control group was observed (Fig. 4). Additionally, 
there were no significant differences in PWL of rats 
during 21-days of the study in CFA+0.9% saline (as a 
vehicle of Minocycline) group (Hence, the results of 
the CFA+0.9% saline groups are not shown 
graphically). 
Variation in spinal Iba-1 expression during 
different stages of study 
In order to check the Iba-1 protein expression 
in the obtained tissues from the lumbar spinal cord of 
all experimental groups, we used polyclonal antibody 
to detect Iba-1 protein as a marker of microglia 
activity in the spinal cord. The analysis showed 
similar bands with molecular weight of almost 17 
 
Fig. 3. CFA injection into the hind paw of rats 
cause significant hyperalgesia at 7th day but, 
hyperalgesia reduced at 14th and 21st days, and 
long-term injection of Minocycline considerably 
decremented thermal hyperalgesia. Results 
presented as Mean ± SEM (n= 6/group).  
** p≤0.01 and *** p≤0.001 for comparing the PWL 
variations in CFA group between day 0 and 
different time points of the study. # p≤0.05 and # # 
p≤0. 01 for comparing the PWL variations in CFA+ 
Minocycline group between day 0 and different 
time points of the study. ††† p≤0.001 for 
comparing the changes in PWL in the CFA+ 
Minocycline group at day 14 and day 21 compared 
to day 7. 
 
Fig. 4. CFA injection considerably raise thermal 
hyperalgesia while Minocycline administration 
reduced thermal hyperalgesia compared to the CFA 
group. Results stated as Mean± SEM (n=6/group).  
** p≤0.01 and *** p≤0.001 for Comparing the 
PWL variations between CFA and CFA+ 
Minocycline groups in identical days. # # # 
P≤0.001 for comparing the differences in PWL 
variations in CFA and CFA+ Minocycline groups 
at days 14 and 21 compared to day 7. 
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KDa which was the same as the manufacturer’s 
instructions. Immunospecificity was confirmed by the 
absence of immunoreactive bands when the 
membrane was preincubated with an antigenic peptide 
prior to antibody incubation (data not shown) (26). 
Following quantification of mOR-immunoreactive 
bands, membranes were stripped and re-probed for β-
actin as a loading control (43 kDa). To normalize 
differences in protein-loading, all data were expressed 
as Iba-1/β-actin ratio. 
Our results confirm that, on the lumbar part of 
the spinal cords obtained from the CFA-induced 
inflammation rats, spinal Iba-1 protein expression 
observably increased on days 7, 14, and 21 compared 
to day 0 of the study (p≤0.001, p≤0.001 and  p≤0.01 
respectively) (Fig. 5). There was no significant 
difference in Iba1 expression in the CFA control 
group. In the CFA+ Minocycline group, CFA 
injection into the right hind paw caused a significant 
increase in Iba-1 expression on day 7 compared to 
 
Fig. 5. CFA injection into the hind paw of rats cause significant hyperalgesia at 7th day but, hyperalgesia 
reduced at 14th and 21st days, and long-term injection of Minocycline considerably decremented thermal 
hyperalgesia. Results presented as Mean ± SEM (n= 6/group).  
** p≤0.01 and *** p≤0.001 for comparing the PWL variations in CFA group between day 0 and different 
time points of the study. # p≤0.05 and # # p≤0. 01 for comparing the PWL variations in CFA+ Minocycline 
group between day 0 and different time points of the study. ††† p≤0.001 for comparing the changes in PWL 
in the CFA+ Minocycline group at day 14 and day 21 compared to day 7. 
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day 0 (p<0.05). There was no significant difference in 
Iba-1 expression between days 14 and 21 compared to 
day 0 (data not shown). In addition, there were no 
significant differences in Iba-1 expression in rats 
during 21-days of the study in CFA+0.9% saline (as a 
vehicle of Minocycline) group (Hence, the results of 
the CFA+0.9% saline groups are not shown 
graphically). There was a significant difference in 
Iba-1 expression on days 7, 14, and 21 between CFA+ 
Minocycline and CFA groups (p<0.001, p<0.001, and 
p<0.01, respectively) (Fig.5). 
Discussion 
In this study, we show that there is relationship 
between spinal microglia activity and pain behavioral 
symptoms during adjuvant-induced inflammation. In 
this study plantar injection of CFA induced paw 
inflammation and edema which continued up to day 
21 after the CFA injection. Hyperalgesia elevated 
considerably on day 7 after the CFA injection, but the 
continuity of inflammation declined hyperalgesia 
notably on days 14 and 21 of the study compared to 
day 7.  
Arthritis model induced by CFA in rats is an 
inflammatory model extensively used in 
etiopathogenic investigational drug and molecular 
studies due to its similarity to human RA and assay 
the pathophysiological and pharmacological changes 
during human RA (27). Intraplantar injection of 
inflammatory agents such as CFA causes elevated 
firing of peripheral afferents in the spinal cord, 
leading to hyperalgesia (28). Sensitization of the 
primary afferent nociceptive fiber during 
inflammation is an important factor in the creation 
and development of hyperalgesia (11). Pursuant to 
Hargreaves study, rats due to its inflammation 
induced by plantar injection of CFA, had withdrawn 
his affected paw from the thermal stimuli, but some 
other studies have shown that motor behaviors 
subsequent of the inflammation are normal and no 
notable changes in motor activities are observed (29). 
A study illustrated that plantar injection of CFA 
incremented hyperalgesia and edema from 24 hours 
after the CFA injection and continued up to the first 
week after the injection (30). Thermal hyperalgesia 
never happened in the contralateral paw during 
arthritis induced by CFA adjuvant. Injection of CFA 
into the one hind paw may have a pivotal role in the 
induction of hyperalgesia which occurs only in the 
ipsilateral paw, however the reasons for the absence 
of hyperalgesia in the contralateral paw should be 
clarified (31). 
The results of this study indicated the role of 
Minocycline in reducing edema and hyperalgesia 
during different stages of inflammation caused by 
CFA. The continuing injection of Minocycline could 
reduce the inflammatory symptoms. Because these 
results suggest an association between microglial 
activation, which is known to contribute to pain after 
peripheral nerve injury, and hyperresponsiveness of 
pain related behaviors to peripheral stimulation and 
chronic pain after CFA injection. We downregulated 
pharmacologically activation of microglia with the 
inhibitor minocycline. After delivery of minocycline, 
we showed reductions in behavioral concomitants of 
pain, suggesting a role of microglia in the active 
modulation of ongoing below-level pain after CFA 
injection. The precise role of activated microglia in 
CFA induced inflammatory pain has not been studied 
previously, and our finding of a contribution of 
activated microglia to maintaining chronic pain after 
CFA injection is novel. There is a body of literature 
that suggests that microglia are involved in the initial 
phase of development of chronic pain after peripheral 
injury, but the role of microglia in its ongoing 
maintenance of pain has not been reported. Microglial 
activation occurs in response to CNS trauma, 
ischemia, tumors, neurodegeneration and 
immunogenic components of viruses and bacteria 
(32). Glial activation may enhance neuronal 
transmission of nociceptive information. One possible 
mechanism for activated glia to induce hyperalgesia 
and allodynia is through the release of pro-
inflammatory cytokines, such as IL-1β, TNF-α and 
IL-6 (33). In line with these findings, we also 
observed the increased thermal hyperalgesia and 
edema with glial activation following the peripheral 
administration of CFA. 
Conclusion 
This study showed that peripheral 
inflammation induced by CFA causes glial activation 
and deterioration pain related behaviors. The steady 
injection of Minocycline (as a microglia inhibitor) 
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could reduce the inflammatory symptoms. However, 
further studies are needed to evaluate the relationship 
between microglia activity and central cytokines on 
different aspects of inflammation. 
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